ALDH1A1 and lung carcinoma: In erlotinib-resistant lung cancer cells, the upregulated expression of SOD2 and GPX4 induced by aldehyde dehydrogenase 1A1 (ALDH1A1) reduces the ROS-RCS levels caused by erlotinib and endows TKI resistance [102].